Due to the complexity of combination products, drug sponsors may receive several deficiencies and compliance observations—known as 483 observations in the United States. Part two of Adam Lambert’s article clarifies important guidance points to help mitigate the risk surrounding validation of methods and to ensure a robust marketing application.
Our unique approach can help your company navigate the complexities of launching a drug, biologic or medical device into multiple markets. The first step? Connecting. Simply fill out our form and a representative will follow-up shortly.
1.877.787.0177
510.732.0177
Pharmatech Associates, Inc. 9110 Alcosta Blvd. STE H #601 San Ramon CA 94583
